Research Study

XP500: Optimized, Evolutionary ODT Performance

Format: PDF file | Document type: Research Study | Promoted Content

This Research Study has been written by SPI Pharma , and any views and opinions expressed do not necessarily reflect those of

XP500: Optimized, Evolutionary ODT Performance

XP500 is the latest development in the constant improvement of ODT dosage forms. The formulator is required to produce a tablet which is rapidly disintegrating, possesses superior organoleptic characteristics, and is sufficiently durable. The wide functioning characteristics of this new delivery system allow a formulator to make a high dosage (500mg) formula that dissolves in less than 30 seconds.

Supplier info centre